Article
Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Circulation. Heart failure - 1 Mar 2017
Coppini Raffaele, Mazzoni Luca, Ferrantini Cecilia, Gentile Francesca, Pioner Josè Manuel, Laurino Annunziatina, Santini Lorenzo, Bargelli Valentina, Rotellini Matteo, Bartolucci Gianluca, Crocini Claudia, Sacconi Leonardo, Tesi Chiara, Belardinelli Luiz, Tardiff Jil, Mugelli Alessandro, Olivotto Iacopo, Cerbai Elisabetta, Poggesi Corrado
Abstract excerpt
BACKGROUND: Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na+ current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro. METHODS AND RESULTS: To test whether long-term treatment prevents cardiomyopathy in vivo, transgenic mice harboring the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
